Oncogenic RAS signaling not only increases PD‐L1 mRNA stability134 but also leads to mutations of KRAS and TP53 in lung adenocarcinoma, which may imply a reaction to anti‐PD‐1 therapy.135. Here, KRAS is linked to lung adenocarcinoma.